Femasys Inc
Femasys Inc. is a biomedical company. The Company is focused on addressing the unmet needs of women worldwide with a broad portfolio of in-office, accessible, and therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable blended biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. It also developed FemCerv, which is an endocervical tissue sampler for cervical cancer diagnosis; FemVue, which is a companion diagnostic for fallopian tube assessment; FemCath, which is an intrauterine catheter, and FemChec.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Femasys Inc's stock, believing it could rise significantly in value.
Financial Health
Femasys Inc is generating modest revenue and cash flow, but faces challenges with profitability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring FEMY
New Opportunities in Endometriosis Treatment
This carefully selected group of biopharmaceutical stocks represents companies that could benefit from Organon's recent discontinuation of its endometriosis drug. Our analysts have identified these firms as potential leaders in addressing the significant unmet needs in women's health.
Published: July 3, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Early-stage potential
Small market cap means more room for growth if products gain traction, though share prices can swing sharply and outcomes are uncertain.
Regulatory impact
Clinical data and approvals can materially affect prospects; regulatory milestones are catalysts but also carry execution risk.
Market and adoption
Addressing women’s reproductive health can tap large, underserved markets, but commercial uptake and reimbursement may take time.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
